Profile data is unavailable for this security.
About the company
MEI Pharma, Inc. is a clinical-stage pharmaceutical company, which is engaged in developing novel and differentiated cancer therapies. Its drug candidate pipeline includes Voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and ME-344, an intravenous small molecule mitochondrial inhibitor targeting the oxidative phosphorylation pathway. Voruciclib is a potent and selective orally administered CDK9 inhibitor. Voruciclib is being studied in a Phase 1 trial evaluating dose and schedule in patients with acute myeloid leukemia (AML) and B-cell malignancies as a single-agent, and in combination with the B-cell lymphoma 2 (BCL) inhibitor venetoclax (marketed as Venclexta) in patients with AML. ME-344 is a novel mitochondrial inhibitor drug candidate that demonstrates tumor selective activity in pre-clinical studies. It targets the OXPHOS pathway involved in the production of adenosine triphosphate (ATP).
- Revenue in USD (TTM)66.75m
- Net income in USD26.16m
- Incorporated2000
- Employees46.00
- LocationMEI Pharma Inc11455 El Camino Real, Suite 250SAN DIEGO 92130United StatesUSA
- Phone+1 (858) 369-7100
- Fax+1 (302) 655-5049
- Websitehttps://www.meipharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sol Gel Technologies Ltd | 6.56m | -14.92m | 18.04m | 36.00 | -- | 0.5169 | -- | 2.75 | -0.5354 | -0.5354 | 0.2355 | 1.25 | 0.1351 | -- | 1.59 | 182,194.40 | -30.72 | -31.60 | -34.59 | -35.49 | -- | -- | -227.40 | -135.76 | -- | -- | 0.00 | -- | -59.98 | 64.50 | -82.52 | -- | -33.78 | -- |
| Bullfrog AI Holdings, Inc. | 65.00k | -6.08m | 18.29m | 4.00 | -- | 3.40 | -- | 281.41 | -0.8441 | -0.8441 | 0.009 | 0.6860 | 0.0107 | -- | -- | 16,250.00 | -100.10 | -- | -117.94 | -- | 92.00 | -- | -9,331.34 | -- | -- | -328.51 | 0.0596 | -- | 550.00 | -- | -91.11 | -- | -- | -- |
| Biomx Inc | 0.00 | -26.25m | 18.36m | 58.00 | -- | -- | -- | -- | -0.4575 | -0.4575 | 0.00 | 0.3929 | 0.00 | -- | -- | 0.00 | -47.79 | -- | -57.76 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.59 | -- | -- | -- |
| Finch Therapeutics Group Inc | 0.00 | -14.17m | 18.40m | 18.00 | -- | 1.29 | -- | -- | -8.82 | -8.82 | 0.00 | 8.86 | 0.00 | -- | -- | -- | -25.20 | -- | -28.80 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -87.57 | -- | 34.80 | -- | -- | -- |
| Spruce Biosciences Inc | 9.57m | -43.11m | 18.49m | 22.00 | -- | 0.3124 | -- | 1.93 | -1.05 | -1.05 | 0.2338 | 1.43 | 0.095 | -- | -- | 330,069.00 | -42.79 | -41.24 | -52.43 | -46.49 | -- | -- | -450.38 | -1,774.39 | -- | -117.26 | 0.0412 | -- | -- | -- | -3.77 | -- | -- | -- |
| Brainstorm Cell Therapeutics Inc | 0.00 | -12.75m | 18.98m | 29.00 | -- | -- | -- | -- | -0.2242 | -0.2242 | 0.00 | -0.0443 | 0.00 | -- | -- | 0.00 | -223.03 | -117.19 | -- | -231.65 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 29.18 | -- | -45.34 | -- |
| NanoViricides Inc | 0.00 | -9.51m | 19.61m | 7.00 | -- | 1.84 | -- | -- | -0.8115 | -0.8115 | 0.00 | 0.9017 | 0.00 | -- | -- | 0.00 | -63.30 | -43.54 | -65.85 | -46.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.94 | -- | -8.90 | -- |
| Nymox Pharmaceutical Corp | 0.00 | -8.84m | 19.64m | 3.00 | -- | -- | -- | -- | -0.0966 | -0.0966 | 0.00 | -0.0339 | 0.00 | -- | -- | -- | -785.44 | -306.39 | -- | -749.37 | -- | -- | -- | -43,683.47 | -- | -157.57 | -- | -- | -- | -- | -34.49 | -- | -39.16 | -- |
| Goldenwell Biotech Inc | 940.00 | -137.11k | 19.80m | -- | -- | 5,169.71 | -- | 21,063.83 | -0.0014 | -0.0014 | 0.00001 | 0.00004 | 0.0048 | 0.0031 | -- | -- | -69.82 | -- | -70.29 | -- | 42.55 | -- | -14,586.17 | -- | 21.43 | -- | 0.00 | -- | -95.10 | -- | 88.13 | -- | -- | -- |
| Minerva Neurosciences Inc | 0.00 | -33.65m | 19.93m | 9.00 | -- | -- | -- | -- | -4.44 | -4.44 | 0.00 | -6.36 | 0.00 | -- | -- | 0.00 | -59.32 | -49.89 | -62.70 | -52.39 | -- | -- | -- | -442.65 | -- | -- | -- | -- | -- | -- | 6.55 | -- | -- | -- |
| MEI Pharma Inc | 66.75m | 26.16m | 20.26m | 46.00 | 0.7744 | 0.3969 | 0.764 | 0.3034 | 3.93 | 3.93 | 10.02 | 7.66 | 0.6498 | -- | 29.15 | 1,451,174.00 | 25.46 | -25.31 | 30.38 | -28.59 | -- | -- | 39.18 | -122.05 | -- | -- | 0.00 | -- | 19.95 | 97.56 | 41.53 | -- | -- | -- |
| Vincerx Pharma Inc | 0.00 | -28.90m | 20.41m | 42.00 | -- | 1.32 | -- | -- | -1.31 | -1.31 | 0.00 | 0.5206 | 0.00 | -- | -- | 0.00 | -101.76 | -- | -136.61 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 36.24 | -- | -- | -- |
| Pieris Pharmaceuticals Inc | 20.87m | -23.82m | 21.34m | 46.00 | -- | 1.14 | -- | 1.02 | -19.12 | -19.12 | 16.67 | 14.17 | 0.3707 | -- | 17.13 | 453,739.10 | -42.31 | -28.41 | -66.27 | -39.69 | -- | -- | -114.11 | -94.61 | -- | -- | 0.00 | -- | 65.28 | 8.03 | 26.25 | -- | -36.82 | -- |
| Palatin Technologies, Inc. | 5.90m | -32.20m | 21.95m | 34.00 | -- | 13.90 | -- | 3.72 | -2.39 | -2.39 | 0.4275 | 0.0979 | 0.3189 | 0.6402 | 6.95 | 173,588.80 | -173.98 | -26.11 | -387.23 | -30.68 | 96.58 | -- | -545.58 | -126.20 | 1.20 | -- | 0.0443 | -- | 230.53 | -40.87 | 23.91 | -- | 80.82 | -- |
| Geovax Labs Inc | 300.68k | -26.92m | 22.56m | 17.00 | -- | -- | -- | 75.03 | -13.05 | -13.05 | 0.1389 | -0.5526 | 0.0237 | -- | -- | 17,687.06 | -212.40 | -108.34 | -362.39 | -147.24 | -- | -- | -8,951.51 | -1,842.93 | -- | -- | -- | -- | -100.00 | -- | -85.20 | -- | -- | -- |
Data as of Sep 19 2024. Currency figures normalised to MEI Pharma Inc's reporting currency: US Dollar USD
39.07%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Anson Funds Management LPas of 30 Jun 2024 | 1.09m | 16.41% |
| Cable Car Capital LLCas of 30 Jun 2024 | 611.44k | 9.18% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 388.01k | 5.82% |
| Acadian Asset Management LLCas of 30 Jun 2024 | 150.15k | 2.25% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 145.29k | 2.18% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 73.84k | 1.11% |
| Geode Capital Management LLCas of 30 Jun 2024 | 51.29k | 0.77% |
| National Bank Financial, Inc.as of 30 Jun 2024 | 33.00k | 0.50% |
| Macquarie Investment Management Business Trustas of 30 Jun 2024 | 30.00k | 0.45% |
| Bridgeway Capital Management LLCas of 30 Jun 2024 | 26.87k | 0.40% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
